LGND

#1372
Ligand Pharmaceuticals Inc.
232.3400 USD
+8.85%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
232.3400
232.3400
Intervallo Annuale
175.8900
232.3400
Variazione giornaliera
+8.85%
Variazione Mensile
+13.72%
Variazione di 6 mesi
+24.17%
Variazione Annuale
+24.17%
Chiusura Precedente
213.4400
Apertura
232.3400
Bid
Ask
Minimo
232.3400
High
232.3400
Volume
44
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Dividendi
Trimestrale Annuale
  • Market Capitalization 4.6331 B
  • Employee 47
  • Founded N/A
  • CEO N/A
  • Website www.ligand.com
  • Headquarter Delaware, United States
  • FIGI BBG000BKF014
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
30.84
Rapporto prezzo/fatturato
14.31
Dividendi per azione
2.5
Rendimento da dividendi %
1.32

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020.

Notizie